<DOC>
	<DOCNO>NCT00791778</DOCNO>
	<brief_summary>Comparison Nexavar placebo maintenance therapy patient advance Ovarian primary Peritoneal cancer complete remission follow surgery one regimen chemotherapy .</brief_summary>
	<brief_title>Comparison Nexavar/Placebo Maintenance Therapy Patients With Advanced Ovarian Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirm International Federation Gynecology Obstetrics ( FIGO ) stage ( 67 ) III IV ovarian epithelial cancer primary peritoneal cancer presentation . Patients must achieve clinical complete response ( disappearance clinical radiological evidence tumor ) one regimen ( 46 cycle ) platinum taxanebased standard chemotherapy receive tumor debulkment . Normal serum CA125 ( cancerassociated tumor marker ) level within 7 day first dose sorafenib . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . All scan use document complete response must do within 30 day prior randomization . Patients must able swallow retain oral medication . Patients residual cancer tissue completion chemotherapy detectable standard Computed tomography ( CT ) magnetic resonance imaging ( MRI ) . Prior local radiotherapy , neoadjuvant chemotherapy intraperitoneal chemotherapy . Histologic subtypes ovarian cancer epithelial ( i.e . sarcoma , lymphoma , germ cell ) . Major surgery , open biopsy , significant traumatic injury within 30 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Peritoneal Neoplasma</keyword>
</DOC>